{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:01:15Z","timestamp":1789851675543,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier","isbn-type":[{"value":"9780443297229","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.018","type":"book-chapter","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:29:20Z","timestamp":1759922960000},"page":"113-132","source":"Crossref","is-referenced-by-count":3,"title":["Rescue therapy in myasthenia gravis"],"prefix":"10.1016","member":"78","reference":[{"issue":"7","key":"10.1016\/bs.irn.2025.04.018_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/1744666X.2022.2084074","article-title":"An update on the use of immunoglobulins as treatment for myasthenia gravis","volume":"18","author":"Alcantara","year":"2022","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.018_bib2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s13760-016-0689-z","article-title":"A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients","volume":"117","author":"Alipour-Faz","year":"2017","journal-title":"Acta Neurologica Belgica"},{"issue":"23","key":"10.1016\/bs.irn.2025.04.018_bib3","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.018_bib4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","article-title":"Intravenous immunoglobulin: Adverse reactions and management","volume":"122","author":"Bonilla","year":"2008","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.018_bib5","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study [published correction appears in","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.018_bib6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: The ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"Journal of Clinical Apheresis"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.018_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/muscles3010005","article-title":"Eculizumab as additional rescue therapy in myasthenic crisis","volume":"3","author":"Crescenzo","year":"2024","journal-title":"*Muscles*"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.018_bib8","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s13311-021-01108-4","article-title":"Update on intravenous immunoglobulin in neurology: Modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy","volume":"18","author":"Dalakas","year":"2021","journal-title":"Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics"},{"issue":"21","key":"10.1016\/bs.irn.2025.04.018_bib9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.018_bib10","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.21037\/jtd-22-1589","article-title":"Outcomes after thymectomy in non-thymomatous myasthenia gravis","volume":"15","author":"Deboever","year":"2023","journal-title":"Journal of Thoracic Disease"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.018_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","article-title":"IVIG versus PLEX in the treatment of worsening myasthenia gravis: What is the evidence?: A critically appraised topic","volume":"19","author":"Dhawan","year":"2015","journal-title":"The Neurologist"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.018_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"Elovaara","year":"2008","journal-title":"European Journal of Neurology"},{"key":"10.1016\/bs.irn.2025.04.018_bib13","series-title":"Myasthenia gravis and related disorders","first-page":"189","article-title":"Neurocritical care of myasthenic crisis","author":"Fernandes","year":"2018"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.018_bib14","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mus.24960","article-title":"Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis","volume":"53","author":"Furlan","year":"2016","journal-title":"Muscle & Nerve"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.018_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Annals of\u00a0Neurology"},{"issue":"23","key":"10.1016\/bs.irn.2025.04.018_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.0000000000007605","article-title":"Efgartigimod: A novel antibody depletion therapy in myasthenia gravis","volume":"92","author":"Guidon","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.018_bib17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.018_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","article-title":"Update on MuSK antibody positive myasthenia gravis","volume":"23","author":"Guptill","year":"2010","journal-title":"Current Opinion in Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.018_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle & Nerve"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.018_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","article-title":"Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: An acute hospital cost comparison study","volume":"13","author":"Heatwole","year":"2011","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.018_bib21","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): A multicenter, randomized, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"*Lancet Neurol**"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.018_bib22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1016\/bs.irn.2025.04.018_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: A systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Frontiers in Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.018_bib24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/CND.0b013e3181660807","article-title":"A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis","volume":"9","author":"Jensen","year":"2008","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"10.1016\/bs.irn.2025.04.018_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740517","article-title":"A retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion","volume":"12","author":"Kato","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.018_bib26","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1007\/s00415-024-12234-2","article-title":"Ravulizumab in myasthenic crisis: The first case report","volume":"271","author":"Konen","year":"2024","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.018_bib27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nature Reviews. Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.018_bib28","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.018_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmunity Reviews"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.018_bib30","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/mus.27220","article-title":"Thymoma pathology and myasthenia gravis outcomes","volume":"63","author":"Menon","year":"2021","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.018_bib31","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.018_bib32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: A U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle & Nerve"},{"issue":"13","key":"10.1016\/bs.irn.2025.04.018_bib33","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.018_bib34","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: A systematic review and meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicines"},{"issue":"3S","key":"10.1016\/bs.irn.2025.04.018_bib35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: A review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.018_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.33588\/rn.3305.2001132","article-title":"Estudio comparativo entre inmunoglobulina intravenosa y plasmaf\u00e9resis en el perioperatorio de la miastenia gravis [A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia]","volume":"33","author":"P\u00e9rez Nellar","year":"2001","journal-title":"Revista de Neurologia"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.018_bib37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1212\/WNL.52.3.629","article-title":"Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis","volume":"52","author":"Qureshi","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.018_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/nsn.nsn_175_22","article-title":"High-dose steroids versus standard treatment for myasthenic crisis: A single-center, longitudinal, 12-year retrospective study","volume":"40","author":"Rabor","year":"2023","journal-title":"*Neurol Sci Neurophysiol**"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.018_bib39","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/WCO.0000000000001189","article-title":"Thymectomy in myasthenia gravis","volume":"36","author":"Rath","year":"2023","journal-title":"Current Opinion in Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.018_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bjh.12629","article-title":"The mechanisms of action of plasma exchange","volume":"164","author":"Reeves","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"5503","key":"10.1016\/bs.irn.2025.04.018_bib41","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science (New York, N. Y.)"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.018_bib42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nri3401","article-title":"Intravenous immunoglobulin therapy: How does IgG modulate the immune system?","volume":"13","author":"Schwab","year":"2013","journal-title":"Nature Reviews. Immunology"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.018_bib43","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archneur.1993.00540080046012","article-title":"Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin","volume":"50","author":"Stricker","year":"1993","journal-title":"Archives of Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.018_bib44","article-title":"Successful control of myasthenic crisis after the introduction of ravulizumab in myasthenia gravis: A case report","volume":"16","author":"Uchi","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.018_bib45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"*Muscle & Nerve**"},{"key":"10.1016\/bs.irn.2025.04.018_bib46","article-title":"Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod","volume":"15","author":"Watanabe","year":"2024","journal-title":"*Frontiers in Neurology*"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.018_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"issue":"21","key":"10.1016\/bs.irn.2025.04.018_bib48","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMx170003","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"376","author":"Wolfe","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.irn.2025.04.018_bib49","first-page":"1401972","article-title":"Case report: Rapid clinical improvement in acute exacerbation of MuSK-MG with efgartigimod","volume":"15","author":"Zhu","year":"2024","journal-title":"*Frontiers in Neurology*"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.018_bib50","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV Immunoglobulin in patients with myasthenia gravis: A randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774225000339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:57:38Z","timestamp":1760500658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774225000339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443297229"],"references-count":50,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.018","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}